Madrigal Pharmaceuticals has agreed to enter into a global license agreement with CSPC Pharmaceutical Group Limited for its preclinical oral small molecule glucagon-like-peptide-1 (GLP-1) receptor agonist SYH2086. Alongside SYH2086, Madrigal also got the exclusive global license for CSPC’s orforglipron derivative and plans to commence clinical developments staring in the first half of 2026.
Key Takeaways
- The exclusive global agreement will allow Madrigal to strategically expand its MASH treatment options.
- The agreement enhances SYH2086’s clinical potential.
- CSPC will receive a financial boost with $120 million upfront and the chance to increase the agreements value to $2 billion.
Bill Sibold, chief executive officer of Madrigal, made note of what the agreement means for Madrigal and its future, saying, “We’ve made remarkable progress this year advancing our strategic priorities–from the continued successful launch of Rezdiffra, to securing new IP protection through 2044, to laying the groundwork for Rezdiffra’s next stages of growth in F4c and Europe. This agreement to acquire global rights to SYH2086 aligns perfectly with our long-term goal to extend our leadership in MASH by building a pipeline anchored by Rezdiffra. We believe a combination of Rezdiffra and SYH2086 has the potential to deliver a best-in-class oral treatment for patients with MASH.”1
Bashing MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease progressing cirrhosis, liver failure, liver cancer, liver transplant necessity, and can lead to premature fatality. MASH is the leading cause of liver transplants in women, while also being the second leading cause of liver transplants across the U.S. Patients diagnosed with MASH can progress to moderate or advanced liver fibrosis, which raises the risk of severe liver outcomes and highlights the need to treat MASH in a timely and effective manner.
Dongchen Cai, chairman of the board at CSPC touched further on the topic saying, “We are pleased to announce the in-license of our oral GLP-1 by Madrigal, an innovative company that pioneered the first approved treatment for MASH. We believe Madrigal’s strong clinical development and commercial capabilities will help unlock the full potential of SYH2086 to benefit patients.”1